News

The trial supports the company’s larger clinical program of CVC in non-alcoholic steatohepatitis (NASH), a disease associated with multiple comorbidities, including diabetes. The company said that pioglitazone is

Currently, VS-5584 is being evaluated in a Phase I clinical trial in patients with advanced solid tumors and a Phase I combination trial with VS-6063 (defactinib) in patients

The open-label, dose-escalating Phase I/II trial is designed to evaluate the safety and preliminary efficacy of sub-retinal administration of SPK-CHM. Spark co-founder and chief executive officer Jeffrey Marrazzo

Vayacog is a proprietary prescription medical food that offers phosphatidylserine enriched with DHA, a lipid composition essential to manage key biochemical modifications underlying losses in brain function. The

The ten-year indefinite delivery/indefinite quantity contract will see DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, supporting and conducting Phase I clinical trials of infectious

Based on the antioxidant supplement used in The National Eye Institute’s (NEI) AREDS 2 study, ProVision leverages today’s best research on nutritional support for macular health to create

Phoxillum, a pre-mixed solution containing phosphate in a 5l bag, is designed to treat hypophosphatemia in patients receiving CRRT, such as in an intensive care environment for patients

Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. Currently, there are no approved therapies for DMD in the US, where it affects around 20,000 people. The company

Administered as a once-daily single injection independently of meals, Xultophy is a combination of basal insulin Tresiba (insulin degludec) and GLP-1 analogue Victoza (liraglutide). The product is intended